(3aR,6aS)-5-[3-(cyclopentyloxy)-4-methoxyphenyl]octahydro-2-pentalenol | 439919-39-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: (3aR,6aS)-5-[3-(cyclopentyloxy)-4-methoxyphenyl]octahydro-2-pentalenol
• CAS: 439919-39-8
• 化学式: C₂₀H₂₈O₃
• 分子量: 316.441
• InChiKey: LAWSGPCAOSXGTF-DSPLQEQRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.28
• 重原子数：
  23.0
• 可旋转键数：
  4.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  38.69
• 氢给体数：
  1.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  (3aR,6aS)-5-[3-(cyclopentyloxy)-4-methoxyphenyl]octahydro-2-pentalenol 在 吡啶 、 N-甲基吲哚酮 、 四丙基高钌酸铵 、 zinc(II) iodide 、 三氯氧磷 作用下， 以 二氯甲烷 为溶剂， 反应 27.5h， 生成 (3aRS,5SR,6aRS)-5-[3-(cyclopentyloxy)-4-methoxyphenyl]-1,3a,4,5,6,6a-hexahydro-2-pentalenecarbonitrile
  参考文献：
  名称：

  Design, synthesis, and biological evaluation of new phosphodiesterase type 4 inhibitors

  摘要：

  The design, synthesis, and biological evaluation of new phosphodiesterase type 4 inhibitors, which possess new templates instead of a cyclohexane ring, are described. The mode of interaction with the enzyme is discussed based on the structure-activity relationship (SAR) data obtained for the synthesized inhibitors. Furthermore, the roles of three pharmacophores, a catechol moiety, a nitrile moiety, and acidic moieties, are discussed using in silico docking studies. More detailed biological evaluations of selected compounds are also presented. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.07.040
• 作为产物：
  描述：

  (3aRS,6aSR)-5-[3-(cyclopentyloxy)-4-methoxyphenyl]-3,3a,4,6a-tetrahydro-2(1H)-pentalenone 在 Crabtree's catalyst sodium tetrahydroborate 、 氢气 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 2.0h， 生成 (3aR,6aS)-5-[3-(cyclopentyloxy)-4-methoxyphenyl]octahydro-2-pentalenol
  参考文献：
  名称：

  Design, synthesis, and biological evaluation of new phosphodiesterase type 4 inhibitors

  摘要：

  The design, synthesis, and biological evaluation of new phosphodiesterase type 4 inhibitors, which possess new templates instead of a cyclohexane ring, are described. The mode of interaction with the enzyme is discussed based on the structure-activity relationship (SAR) data obtained for the synthesized inhibitors. Furthermore, the roles of three pharmacophores, a catechol moiety, a nitrile moiety, and acidic moieties, are discussed using in silico docking studies. More detailed biological evaluations of selected compounds are also presented. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.07.040